Atezolizumab after surgery for malignant pleural mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign informed consent.
- Your cancer diagnosis is malignant pleural mesothelioma confirmed by pathology (tissue testing).
- You had surgery to remove the tumor with no visible remaining cancer (certain early cases may have total pleurectomy).
- After surgery, scans show no measurable or trackable cancer.
- You completed at least 4 cycles of platinum plus pemetrexed chemotherapy (or fewer only if your doctor made a clinical decision).
- You can provide tumor tissue for research testing (submitted as a stored tissue block or tissue slides before starting treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests if a partial surgery called pleurectomy can help people with a specific type of mesothelioma that cannot be fully removed. You must have already completed at least 6 weeks of chemotherapy or immunotherapy without the cancer growing.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
Hear when a new Mesotheliomas Pleural trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.